<?xml version="1.0" encoding="UTF-8"?>
<p>LDV/SOF was well‐tolerated with no treatment discontinuations due to AEs in SHARED‐2 participants (0%; 95% CI: 0, 6; Fig. 
 <xref rid="hep41482-fig-0002" ref-type="fig">2</xref>) or in SHARED‐1 participants (0%; 95% CI: 0, 2).
</p>
